Lupin has partnered with Mylan N.V. to commercialise Lupin’s biosimilar Enbrel (etanercept) used in treating certain autoimmune diseases. Mylan would commercialise Lupin’s proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.
Enbrel is a TNF-inhibitor used to treat autoimmune diseases including rheumatoid arthritis. Under the pact, Lupin will receive an upfront payment of $15 million and potential commercial milestones together with an equal share in net profits of the product, the two drugmakers said in a joint statement.
Enbrel had global brand sales of approximately $11.6 billion for the 12 months ending December 31, 2017.
Vinita Gupta, CEO, Lupin Limited said, “This partnership will bring affordable and high quality medicines to market, especially in areas of unmet need. Mylan is well-positioned to commercialise our Etanercept biosimilar given their significant expertise and global infrastructure. This partnership enables us to accelerate our Etanercept market plans across multiple regions globally, as we continue to advance our pipeline of biosimilar candidates.”
Lupin successfully completed its Etanercept biosimilar Phase 3 clinical trial in February 2018. Lupin has filed the product with the European Medicines Agency and plans to file the product in other jurisdictions.
